Drug-Coated Balloons (DCB): Sirolimus vs. Paclitaxel in De Novo Lesions in Small Vessels

The use of drug-coated balloons (DCB) offers the advantage of avoiding permanent stent implants, thus reducing the incidence of in-stent restenosis (ISR), neoatherosclerosis, and late in-stent thrombosis. Additionally, the use of DCB reduces the duration of dual antiplatelet therapy.

Balones cubiertos de fármacos (DCB): Sirolimus vs Paclitaxel en lesiones de novo en vasos pequeños

Current evidence supports the use of DCB for ISR treatment (Class I) compared with drug-eluting stents (DES), and there is also evidence in favor of its application in small vessel disease (SVD). The most studied DCBs are paclitaxel-coated balloons (PCB), and there is no data on sirolimus-coated balloons (SCB).

The aim of this prospective, randomized, multicenter non-inferiority study was to compare quantitative coronary angiography at 6 months in the treatment of SVD with PCB versus SCB. The primary endpoint (PEP) was minimal lumen diameter (MLD) within the DCB-treated area.

Researchers analyzed a total of 109 patients with 117 treated lesions, with 61 lesions randomized to SCB and 56 lesions to PCB. The mean age was 70 years in the SCB group and 67 years in the PCB group. Most patients were men. The most frequently treated arteries were the diagonal branch (23%) and the marginal branch (23%).

Read also: Cilostazol in Diabetic Patients with Endovascular Peripheral Revascularization: One Step Beyond Symptom Improvement.

Regarding the results, the mean MLD was 0.25 ± 0.40 mm with SCB versus 0.48 ± 0.37 mm with PCB, failing to meet the non-inferiority criterion (P non-inferiority = 0.173). The restenosis rate was 32.8% for the SCB group and 12.5% for the PCB group (odds ratio [OR]: 3.41; 95% confidence interval [CI]: 1.36-9.44; P = 0.012).

Conclusion

This randomized study has demonstrated that SCB does not achieve non-inferiority compared with PCB in angiographic outcomes at 6 months. Long-term studies with a larger number of patients are needed to increase statistical power and determine the efficacy of SCB compared with PCB in de novo lesions.

Dr. Andrés Rodríguez.
Member of the Editorial Board of SOLACI.org.

Original Title: A Prospective Randomized Trial Comparing Sirolimus-Coated Balloon With Paclitaxel-Coated Balloon in De Novo Small Vessels.

Reference: Kai Ninomiya, MD et al J Am Coll Cardiol Intv 2023.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

iFR- vs. FFR-Guided Coronary Revascularization: 5-Year Clinical Outcomes

The assessment of coronary stenosis using coronary physiology has become a key tool in guiding revascularization. The two most widely used techniques are fractional...

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...

ACC 2025 | FLAVOUR II: Angiography-Derived FFR-Guided vs. IVUS-Guided PCI

Physiological assessment is effective when it comes to decision-making for percutaneous coronary intervention (PCI). However, despite the available evidence, its use remains limited. AngioFFR...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

SMART-CHOICE 3 | Efficacy and Safety of Clopidogrel vs Aspirin Monotherapy in High Risk Patients after Percutaneous Coronary Intervention

Courtesy of Dr. Juan Manuel Pérez. After post percutaneous coronary intervention (PCI) standard duration dual antiplatelet therapy (DAPT), the optimal long term monotherapy strategy is...

RACE Trial: Effect of Balloon Pulmonary Angioplasty and Riociguat on Right Ventricular Afterload and Function in Chronic Thromboembolic Pulmonary Hypertension

Even though pulmonary endarterectomy is the treatment of choice for chronic thromboembolic pulmonary hypertension (CTEPH), up to 40% of patients are not candidates because...

iFR- vs. FFR-Guided Coronary Revascularization: 5-Year Clinical Outcomes

The assessment of coronary stenosis using coronary physiology has become a key tool in guiding revascularization. The two most widely used techniques are fractional...